4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity
Open Access
- 1 November 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (23) , 10848-10866
Abstract
Despite the high diversity of histamine H3 receptor (H3R) antagonist/inverse agonist structures, partial or full H3R agonists have typically been imidazole derivatives. An in-house screening campaign intriguingly afforded the non-imidazole 4-(3-azetidin-1-yl)pyrimidin-2-amine 11b as partial H3R agonist. Here, the design, synthesis and structure-activity relationships of 11b analogues are described. This series yields several non-imidazole full agonists with potencies varying with the alkyl substitution pattern on the basic amine following the in vitro evaluation of H following the in vitro evaluation of H3R agonism using a CRE-luciferase reporter gene assay. Key compound VUF16839 (14d, combines nanomolar on-target activity (pKi = 8.5, pEC50 = 9.5) with weak activity on CYP enzymes and good metabolic stability. The proposed H3R binding mode of 14d indicates key interactions similar to those attained by histamine. In vivo evaluation of 14d in a social recognition test in mice, revealed an amnesic effect at 5 mg/kg i.p. The excellent in vitro and in vivo pharmacological profile and the non-imidazole structure of 14d make it a promising tool compound in H3R research.Keywords
Funding Information
- Uniwersytet Jagielloński Collegium Medicum (N42/DBS/000039.)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (201511/2014-2)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (718.014.002)
This publication has 73 references indexed in Scilit:
- Colloidal Aggregation Causes Inhibition of G Protein-Coupled ReceptorsJournal of Medicinal Chemistry, 2013
- Identification and Characterization of ZEL-H16 as a Novel Agonist of the Histamine H3 ReceptorPLOS ONE, 2012
- Histamine 3 Receptor Activation Reduces the Expression of Neuronal Angiotensin II Type 1 Receptors in the HeartThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Crystal Structure-Based Virtual Screening for Fragment-like Ligands of the Human Histamine H1 ReceptorJournal of Medicinal Chemistry, 2011
- Several down, a few to go: histamine H3receptor ligands making the final push towards the market?Expert Opinion on Investigational Drugs, 2011
- Structure of the human histamine H1 receptor complex with doxepinNature, 2011
- Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitusProceedings of the National Academy of Sciences, 2006
- Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validationJournal of Computational Chemistry, 2002
- GROMACS: A message-passing parallel molecular dynamics implementationComputer Physics Communications, 1995
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973